MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

Resistance to endocrine therapy in estrogen receptor-positive (ER(+)) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic targeting. We evaluated the mechanism by which minichrom...

全面介紹

Na minha lista:
書目詳細資料
發表在:NPJ Breast Cancer
Main Authors: Løkkegaard, Sanne, Elias, Daniel, Alves, Carla L., Bennetzen, Martin V., Lænkholm, Anne-Vibeke, Bak, Martin, Gjerstorff, Morten F., Johansen, Lene E., Vever, Henriette, Bjerre, Christina, Kirkegaard, Tove, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Lindström, Linda S., Esserman, Laura J., Lykkesfeldt, Anne E., Andersen, Jens S., Leth-Larsen, Rikke, Ditzel, Henrik J.
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2021
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782683/
https://ncbi.nlm.nih.gov/pubmed/33398005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-00210-8
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍